Cefprozil dry suspension, a subsidiary of Sinopharm, passed the consistency evaluation

Original title: cefprozil dry suspension, a subsidiary of Sinopharm, passed the consistency evaluation
Beijing News (reporter Liu Xu) on September 10, Sinopharm announced that the wholly-owned subsidiary Sinopharm Shantou Jinshi Pharmaceutical Co., Ltd. (hereinafter referred to as "Sinopharm Jinshi") cefprozil dry suspension (0.25g) was approved to pass the consistency evaluation of generic drug quality and efficacy. Sinopharm Jinshi was used to evaluate the consistency of cefprozil dry suspension (0.25g), with a cumulative R & D investment of about RMB 3.48 million.
Cephalosporin is a long-acting, broad-spectrum second generation cephalosporin antibiotic. It is commonly used to treat infectious diseases caused by sensitive bacteria, including upper respiratory tract infection, lower respiratory tract infection, skin and soft tissue infection. The drug was developed by Bristol Myers Squibb in the United States and was first listed in the United States in 1991.
According to the data of PDB drug comprehensive database, the global sales of cefprozil dry suspension in 2020 was USD 117.2 million; The sales volume of domestic sample hospitals was 130.9 million yuan. CDE website shows that Sinopharm Jinshi is the second enterprise to pass the consistency evaluation of cefprozil dry suspension (0.25g) after Hainan rizhongtian Pharmaceutical Co., Ltd.
Proofread Lucy